Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 11;31(7):903-914.
doi: 10.1093/eurjpc/zwae032.

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Pia R Kamstrup  1   2 , R Dermot G Neely  3 , Steven Nissen  4 , Ulf Landmesser  5   6   7   8 , Arash Haghikia  5   6   7   8 , Madlaina Costa-Scharplatz  9 , Cheryl Abbas  10 , Børge G Nordestgaard  1   2
Affiliations
Review

Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research

Pia R Kamstrup et al. Eur J Prev Cardiol. .

Abstract

Lipoprotein(a) (Lp(a)) is a genetically determined causal risk factor for cardiovascular disease including coronary heart disease, peripheral arterial disease, ischaemic stroke, and calcific aortic valve stenosis. Clinical trials of specific and potent Lp(a)-lowering drugs are currently underway. However, in clinical practice, widespread assessment of Lp(a) is still lacking despite several guideline recommendations to measure Lp(a) at least once in a lifetime in all adults to identify those at high or very high risk due to elevated levels. The present review provides an overview of key findings from observational and genetic Lp(a) studies, highlights the main challenges in observational Lp(a) studies, and proposes a minimum set of requirements to enhance the quality and harmonize the collection of Lp(a)-related data. Adherence to the recommendations set forth in the present manuscript is intended to enhance the quality of future observational Lp(a) studies, to better define thresholds for increased risk, and to better inform clinical trial design. The recommendations can also potentially assist in the interpretation and generalization of clinical trial findings, to improve care of patients with elevated Lp(a) and optimize treatment and prevention of cardiovascular disease.

Keywords: Cardiovascular risk; Clinical Lp(a) guidelines; Lipoprotein(a); Minimum set of requirements; Observational studies.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: P.R.K. reports talks and consultancies sponsored by the Physicians’ Academy for Cardiovascular Education, Silence Therapeutics, Novartis, and the PCSK9 Forum. R.D.G.N. reports consultancies and talks sponsored by Amgen, Novartis, and Pfizer. S.N. reports that the Cleveland Clinic Center for Clinical Research has received funding to perform clinical trials from AbbVie, AstraZeneca, Amgen, Arrowhead, Bristol Myers Squibb, Eli Lilly, Esperion, Medtronic, MyoKardia, New Amsterdam Pharmaceuticals, Novartis, Pfizer, and Silence Therapeutics. The author receives no personal remuneration for participation in these trials. U.L. reports receiving institutional research grants from Abbott, Amgen, Bayer, and Novartis as well as lecture or consultant honoraria from Abbott, Amgen, Novartis, Sanofi, and Novo Nordisk. A.H. reports consultancies and talks sponsored by Novo Nordisk, Novartis, Bayer, and AstraZeneca. M.C.-S. and C.A. are employees of Novartis. B.G.N. reports consultancies and talks sponsored by AstraZeneca, Sanofi, Regeneron, Akcea Therapeutics, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Silence Therapeutics, Abbott, Ultragenyx, and Esperion.

Comment in

Publication types

Grants and funding

LinkOut - more resources